CLDN18 and neoplasm: Subsequently, therapy‐related target genes were detected: HER2 staining was negative; MLH1, MSH2, MSH6, and PMS2 were positive; Combined Positive Score of Programmed Death‐Ligand 1 (clone number 28‐8) staining was ≥ 5%; and CLDN18.2 was positive (defined as ≥75% of tumor cells showing moderate‐to‐strong membranous CLDN18 staining, determined by using the investigational VENTANA CLDN18 RxDx Assay).